HIF-2α-targeted interventional chemoembolization multifunctional microspheres for effective elimination of hepatocellular carcinoma-Reference-Cited by-同舟云学术

HIF-2α-targeted interventional chemoembolization multifunctional microspheres for effective elimination of hepatocellular carcinoma

Published:2022-05 Issue: Volume:284 Page:121512
ISSN:0142-9612
Container-title:Biomaterials
language:en
Short-container-title:Biomaterials

Author:

Chen Minjiang,Shu Gaofeng,Lv Xiuling,Xu Xiaoling,Lu Chenying,Qiao Enqi,Fang Shiji,Shen Lin,Zhang Nannan,Wang Jun,Chen Chunmiao,Song Jingjing,Liu Zhuang,Du Yongzhong^ORCID,Ji Jiansong

Publisher

Elsevier BV

Subject

Mechanics of Materials,Biomaterials,Biophysics,Ceramics and Composites,Bioengineering

Reference55 articles.

1. EASL clinical practice guidelines: management of hepatocellular carcinoma;J. Hepatol.,2018

2. Current and future treatment of hepatocellular carcinoma: an updated comprehensive review;Daher;J. Clin. Trans. Hepatol.,2018

3. Hepatocellular carcinoma;Forner;Lancet,2018

4. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial;Meyer;Lancet Gastroenterol. Hepatol.,2017

5. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial;Kudo;Gut,2020

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Corrigendum to “HIF-2α-targeted interventional chemoembolization multifunctional microspheres for effective elimination of hepatocellular carcinoma” [Biomaterials 284 (2022) 121512];Biomaterials;2024-12

2. Hypoxia as a Target for Combination with Transarterial Chemoembolization in Hepatocellular Carcinoma;Pharmaceuticals;2024-08-11

3. Fusible and Radiopaque Microspheres for Embolization;Advanced Materials;2024-08-09

4. Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis;Journal of Hepatocellular Carcinoma;2024-08

5. Nanodrugs based on co-delivery strategies to combat cisplatin resistance;Journal of Controlled Release;2024-06